The Association of the British Pharmaceutical Industry (ABPI) has today published details of payment to the Department of Health under the five-year Pharmaceutical Price Regulation Scheme (PPRS).
The figures show that the companies which are voluntarily signed up to the scheme have paid £367million ($526 million) between September 2015 and March 2016, taking total payments to £1.296 billion. However, the overall spend on medicines covered by the scheme has remained flat over the past 12 months.
Measured Spend | |
PPRS Year 2014/15 – comprising Q4 2014 + Q1 2015 | £4,117 million |
PPRS Year 2015/16 – comprising Q4 2015 + Q1 2016 | £4,116 million |
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze